^
Association details:
| Biomarker: | HER-2 S310F |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Successful treatment of a patient with Li–Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib
Excerpt:
...our report of a LFS patient with advanced lung adenocarcinoma containing EGFR L858R, ERBB2 S310F, and TP53 germ-line mutations, demonstrating a complete and durable response to afatinib, is the first case of its kind. The patient responded to afatinib completely after failure of multiple lines of chemotherapy.
DOI:
10.4161/cbt.29173
